References
- Soler‐Cataluna J. J., Martinez‐Garcia M. A., Roman S. P., Salcedo E., Navarro M., Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925–31
- Anthonisen N. R., Manfreda J., Warren C. P., Hershfield E. S., Harding G. K., Nelson N. A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204
- Sapey E., Stockley R. A. COPD exacerbations. 2: Aetiology. Thorax 2006; 61: 250–8
- Aaron S. D., Angel J. B., Lunau M., Wright K., Fex C., Le S. N., et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 349–55
- Balbi B., Bason C., Balleari E., Fiasella F., Pesci A., Ghio R., et al. Increased bronchoalveolar granulocytes and granulocyte/macrophage colony‐stimulating factor during exacerbations of chronic bronchitis. Eur Respir J 1997; 10: 846–50
- Selby C., Drost E., Lannan S., Wraith P. K., MacNee W. Neutrophil retention in the lungs of patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 143: 1359–64
- Tsoumakidou M., Tzanakis N., Chrysofakis G., Kyriakou D., Siafakas N. M. Changes in sputum T‐lymphocyte subpopulations at the onset of severe exacerbations of chronic obstructive pulmonary disease. Respir Med 2005; 99: 572–9
- Fujimoto K., Yasuo M., Urushibata K., Hanaoka M., Koizumi T., Kubo K. Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. Eur Respir J 2005; 25: 640–6
- Gompertz S., O'Brien C., Bayley D. L., Hill S. L., Stockley R. A. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 2001; 17: 1112–19
- White A. J., Gompertz S., Bayley D. L., Hill S. L., O'Brien C., Unsal I., et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003; 58: 680–5
- Damiano V. V., Tsang A., Kucich U., Abrams W. R., Rosenbloom J., Kimbel P., et al. Immunolocalization of elastase in human emphysematous lungs. J Clin Invest 1986; 78: 482–93
- Janoff A., Sloan B., Weinbaum G., Damiano V., Sandhaus R. A., Elias J., et al. Experimental emphysema induced with purified human neutrophil elastase: tissue localization of the instilled protease. Am Rev Respir Dis 1977; 115: 461–78
- Senior R. M., Tegner H., Kuhn C., Ohlsson K., Starcher B. C., Pierce J. A. The induction of pulmonary emphysema with human leukocyte elastase. Am Rev Respir Dis 1977; 116: 469–75
- Shapiro S. D. Proteinases in COPD. Chronic obstructive pulmonary disease: Taylor & Francis Group, LCC, P. J Barnes, 2005; 327–65
- Segura‐Valdez L., Pardo A., Gaxiola M., Uhal B. D., Becerril C., Selman M. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 2000; 117: 684–94
- Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: S77–121
- Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease NHLBI/WHO Workshop Report. NIH Publication No. 2701. 2002. Available at: www.gold.copd.com (accessed December 2006).
- Rytila P., Rehn T., Ilumets H., Rouhos A., Sovijarvi A., Myllarniemi M., et al. Increased oxidative stress in asymptomatic current chronic smokers and GOLD Stage 0 COPD. Respir Res 2006; 7: 69
- Djukanovic R., Sterk P. J., Fahy J. V., Hargreave F. E. Standardised methodology of sputum induction and processing. Eur Respir J Suppl 2002; 37: 1s–2s
- Bieth J., Spiess B., Wermuth C. G. The synthesis and analytical use of a highly sensitive and convenient substrate of elastase. Biochem Med 1974; 11: 350–7
- Ingman T., Sorsa T., Konttinen Y. T., Liede K., Saari H., Lindy O., et al. Salivary collagenase, elastase‐ and trypsin‐like proteases as biochemical markers of periodontal tissue destruction in adult and localized juvenile periodontitis. Oral Microbiol Immunol 1993; 8: 298–305
- Holopainen J. M., Moilanen J. A., Sorsa T., Kivela‐Rajamaki M., Tervahartiala T., Vesaluoma M. H., et al. Activation of matrix metalloproteinase‐8 by membrane type 1‐MMP and their expression in human tears after photorefractive keratectomy. Invest Ophthalmol Vis Sci 2003; 44: 2550–6
- Donaldson G. C., Seemungal T. A., Bhowmik A., Wedzicha J. A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–52
- Barnes P. J. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004; 56: 515–48
- Saetta M., Turato G., Maestrelli P., Mapp C. E., Fabbri L. M. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1304–9
- Beeh K. M., Beier J., Kornmann O., Buhl R. Sputum matrix metalloproteinase‐9, tissue inhibitor of metalloprotinease‐1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir Med 2003; 97: 634–9
- Russell R. E., Culpitt S. V., DeMatos C., Donnelly L., Smith M., Wiggins J., et al. Release and activity of matrix metalloproteinase‐9 and tissue inhibitor of metalloproteinase‐1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002; 26: 602–9
- Mercer P. F., Shute J. K., Bhowmik A., Donaldson G. C., Wedzicha J. A., Warner J. A. MMP‐9, TIMP‐1 and inflammatory cells in sputum from COPD patients during exacerbation. Respir Res 2005; 6: 151
- Golub L. M., Lee H. M., Ryan M. E., Giannobile W. V., Payne J., Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non‐antimicrobial mechanisms. Adv Dent Res 1998; 12: 12–26